The Committee for Medicinal Products for Human Use has issued positive opinions for three new medicines and restrictions on the use of two. In addition, a new contraindication is being recommended for Merck’s Brinavess (vernakalant). ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
